A multicenter real-world review of 10 kHz SCS outcomes for treatment of chronic trunk and/or limb pain

Thomas Stauss¹, Faycal El Majdoub², Dawood Sayed³, Gernot Surges⁴, William S. Rosenberg⁵, Leonardo Kapural⁶, Richard Bundschu⁷, Abdul Lalkhen⁸, Nileshkumar Patel¹, Bradford Gliner⁹, Jeyakumar Subbaroyan⁹, Anand Rotte⁹, Deborah R. Edgar¹⁰, Martin Bettag⁴ & Mohammad Maarouf²

¹Advanced Pain Management, Greenfield, Wisconsin
²Department of Stereotactic and Functional Neurosurgery, Cologne Merheim Medical Center, University of Witten/Herdecke, Cologne, Germany
³Department of Anesthesiology and Pain Medicine, University of Kansas Medical Center, Kansas City, Kansas
⁴KH Barmherzige Brüder, Trier, Germany
⁵Center for the Relief of Pain, Kansas City, Missouri
⁶Carolinas Pain Institute, Winston-Salem, North Carolina
⁷Coastal Orthopedics and Pain Medicine, Bradenton, Florida
⁸The Manchester and Salford Pain Centre, Salford, United Kingdom
⁹Nevro Corp, Redwood City, California
¹⁰Commexus Ltd, Dunblane, United Kingdom

Correspondence
Anand Rotte, Nevro Corp, Redwood City, CA. Tel: +1-650-433-3202; Fax: +1-650-252-1403; E-mail: anand.rotte@nevro.com

Funding Information
Nevro Corp.

Received: 12 September 2018; Revised: 20 December 2018; Accepted: 22 December 2018

Annals of Clinical and Translational Neurology 2019; 6(3): 496–507
doi: 10.1002/acn3.720

Abstract

Objectives: High-frequency spinal cord stimulation (HF-SCS) at 10 kHz has proven to be efficacious in the treatment of chronic back and leg pain in a randomized, controlled, trial (SENZA-RCT). However, large observational studies have yet to be published. Therefore, we performed a real-world, multicenter, retrospective, review of therapy efficacy in 1660 patients with chronic trunk and/or limb pain. Methods: Data were collected in a real-world environment and retrospectively sourced from a global database. Included patients were trialed and/or permanently implanted with HF-SCS at 10 kHz between April 2014 and January 2018. We evaluated responder rates at 3, 6, and 12 months post-implantation. Response was defined as ≥50% pain relief from baseline. A last visit analysis included responder rate along with overall change in function, sleep, quality of life, and medication intake versus baseline. Results: Eighty-four percent of our HF-SCS-treated patients had both chronic back and leg pain. At least 70% of patients reported response to therapy throughout 12 months of follow-up. This sustained responder rate was corroborated by the last visit value (74.1%). Most patients reported concomitant improvements in function (72.3%), sleep (68.0%), and quality of life (90.3%) at their last visit versus baseline. Thirty-two percent of patients reported decreased medication intake at their last visit. Interpretation: Sustained and effective pain relief was experienced by >70% of our HF-SCS-treated patients, consistent with the findings of a previously published randomized, controlled, trial. Our review provides complementary evidence to support the treatment of chronic back and leg pain with this therapy.

Introduction

Chronic pain is a pervasive health issue worldwide.¹² It places a substantial burden on society, families, and individuals.³ Low back pain is one of the most prevalent chronic pain syndromes. It affects over 500 million people globally and is the largest single cause of years lived with disability.⁴ Persistent back and/or radicular leg pain secondary to spinal surgery, also known as failed back surgery syndrome (FBSS), is quite a common condition...
in the population with similar levels of prevalence and incidence to rheumatoid arthritis.\textsuperscript{5,6} Despite the availability of numerous treatment modalities, satisfactory pain control remains elusive for many patients.

Interventional pain management specialists have used traditional low-frequency spinal cord stimulation (LF-SCS) to treat FBSS for several decades. Its effectiveness has been established in patients with predominant leg pain.\textsuperscript{7,8} It is generally accepted after decades of experience and research in this area that LF-SCS provides around 50% pain relief in approximately half of patients.\textsuperscript{7} While this is an overall success story for many patients with intractable pain, the therapy has key limitations. Half of patients do not achieve satisfactory pain control, and for many that do initially, long-term studies suggest that therapy effectiveness can diminish after several years.\textsuperscript{10–15} Achieving good outcomes in patients with predominant axial back pain is especially challenging.\textsuperscript{16} In addition, the necessary paresthesia which characterizes successful LF-SCS is uncomfortable for some patients, particularly if they experience overstimulation during postural changes.\textsuperscript{17,18}

New stimulation waveforms offer the opportunity to improve clinical outcomes and provide a more comfortable patient experience. High-frequency spinal cord stimulation (HF-SCS) at 10 kHz has proven to be both effective and safer patient experience. High-frequency spinal cord stimulation (HF-SCS) at 10 kHz has proven to be both effective and safer.
Variables

Patient records were extracted from the database at numerous study time points including baseline, during the trial, and at each scheduled post-implantation follow-up. The last visit assessment was defined as the last clinic or telephone follow-up with the patient at any time after permanent implantation, before the data were pooled for final report.

Baseline data comprised pain intensity score measured using an 11-point verbal numeric rating scale (VNRS; 0 = no pain to 10 = worst possible pain), pain distribution, and previous LF-SCS experience (if any). Data from the trial included pain intensity score (VNRS) and percentage pain relief obtained from the therapy (0% = no pain relief to 100% = complete pain relief). The latter variable was also extracted from each post-implantation follow-up.

From the last visit, variables were extracted relating to the usage of additional therapy optimization tools (10 kHz preferred program), overall change in medication (increased, decreased, or unchanged), function (improved: yes or no), and sleep (improved: yes or no). In USA, additional variables relating to overall change in quality of life (a great deal better, moderately better, or no change), satisfaction with therapy, device recharge experience, frequency of therapy adjustments, and device usage while sleeping and driving were extracted. All variables were patient-reported except those relating to therapy optimization.

Therapy response was evaluated from the percentage pain relief documented during the trial, at each scheduled post-implantation follow-up, and at the last visit. Response to therapy was defined as at least 50% pain relief from baseline.

Statistical methods

Descriptive analysis of continuous variables included median, 25th (Q1) and 75th (Q3) percentiles. Categorical variables were reported as counts and percentages with 95% confidence intervals (CI) where possible. Pain relief data were analyzed by reporting descriptive statistics. As an additional supportive analysis, last visit data were evaluated. All data were analyzed as-observed. Outcomes from this cohort relating to overall change in quality of life, satisfaction with therapy, device recharge experience, frequency of therapy adjustments, and device usage while sleeping and driving were also compared to available commercial data from all implanted patients in USA. These anonymized data were collected in the real-world setting and stored in the global database. In addition, selected outcomes were further analyzed in the subgroup of patients with previously unsuccessful LF-SCS. The number of patients with available data is reported for each measure. All analyses were carried out in Microsoft Excel 2013 (Microsoft, Redmond, WA, USA).

Results

Patient cohort

During the 4-year review period, 1660 patients were treated and/or permanently implanted with HF-SCS at 10 kHz at participating institutions (Fig. 1). Of these, 1603 had percentage pain relief trial data available and were analyzed for therapy response. The same data were available for 844, 600, and 326 patients, at 3, 6, and 12 months post-implantation, respectively, and for 1131 patients at the last visit. As the data were collected in a real-world setting, only a fraction of patients had information at 3, 6, and 12 months, whereas majority had information at last visit assessment. The mean time between implantation and the last visit was 8.9 months (SD ±6.7, median 6.9, range 0.1–33.2).

Patient characteristics

Baseline patient characteristics are presented in Table 1. Pain distribution data were available for 1640 patients. Of these, 43.5% reported back and leg pain, 27.4% predominant back pain, and 12.6% predominant leg pain. Upper back, left arm, and right arm constituted the three main other pain distributions (16.5%). Approximately a quarter of patients (23.9%, N = 1596) had been unsuccessfully treated with LF-SCS in the past. Median pain intensity score for the cohort (N = 1603) was 8.0 (Q1–Q3, 7.0–9.0). Pain distribution was slightly, but significantly different (P = 0.002, chi-square test) between patients included from Europe (N = 479) and the USA (N = 1161) (Table 1). Briefly, of the patients with available pain distribution data, 39.7% in Europe and 45.0% in the USA reported back and leg pain, 24.6% and 28.6% predominant back pain, and 14.8% and 11.7% predominant leg pain, respectively, and 20.5% in Europe and 25.2% in the USA had been unsuccessfully treated with LF-SCS in the past. Median pain intensity scores for patients included from Europe and the USA were 9.0 (Q1–Q3, 8.0–9.5) and 8.0 (Q1–Q3, 7.0–9.0), respectively.

Outcomes

Pain relief and responder rate

At the end of trial time point, 86.9% of all patients (1393/1603) responded to therapy (at least 50% pain relief from baseline).
relief from baseline). Trial responders reported a significant ($P < 0.00001$, Mann–Whitney $U$ test) reduction in pain intensity scores, with median scores reduced from 8.0 (Q1–Q3, 7.0–9.0) to 3.0 (Q1–Q3, 1.0–4.0), a reduction of 62.5%. Furthermore, pain intensity scores (VNRS) were significantly lower at all time points ($P < 0.00001$, Mann–Whitney $U$ test) compared to baseline in the responding patients. Median pain intensity score decreased from 8.0 (Q1–Q3, 7.0–9.0) to 3.0 (Q1–Q3, 2.0–4.0), 3.0 (Q1–Q3, 2.0–4.0), 3.0 (Q1–Q3, 2.0–4.0), and 3.0 (Q1–Q3, 2.0–4.0) at 3, 6, 12 months and the last visit, respectively.

Of the 844 patients with percentage pain relief data available at 3 months post-implantation, 74.6% responded to therapy. This responder rate was sustained throughout 12 months post-implantation (Fig. 2) and was consistent with the last visit value of 74.1% ($N = 1131$). Responder rate was further analyzed according to whether patients were included from Europe or the USA. Though the responder rates appeared to be slightly
Table 1. Patient characteristics at baseline. Data is presented as % (95% confidence lower limit-upper limit).

| Characteristic               | Europe (%)          | USA (%)           | All (%)           |
|-----------------------------|---------------------|-------------------|-------------------|
| **Pain distribution**       | N = 479             | N = 1161          | N = 1640          |
| Back and leg                | 39.7% (36.9%-42.5%) | 45.0% (40.5%-49.5%) | 43.5% (41.1%-45.9%) |
| Predominant back            | 24.6% (22.1%-27.1%) | 28.6% (24.6%-32.6%) | 27.4% (25.2%-29.6%) |
| Predominant leg             | 14.8% (12.8%-16.8%) | 11.7% (8.8%-14.6%) | 12.6% (11.0%-14.2%) |
| Other                       | 20.9% (18.6%-23.2%) | 14.6% (11.4%-17.8%) | 16.5% (14.7%-18.3%) |
| **LF-SCS experience**       | N = 443             | N = 1153          | N = 1596          |
| Prior experience            | 20.5% (16.7%-24.3%) | 25.2% (22.7%-27.7%) | 23.9% (21.8%-26.0%) |
| No prior experience         | 79.5% (75.7%-83.3%) | 74.8% (72.3%-77.3%) | 76.1% (74.0%-78.2%) |
| **Pain intensity**          | N = 479             | N = 1124          | N = 1603          |
| Median pain intensity score | 9.0 (Q1–Q3, 8.0–9.5) | 8.0 (Q1–Q3, 7.0–9.0) | 8.0 (Q1–Q3, 7.0–9.0) |

LF-SCS, Low-frequency spinal cord stimulation; VNRS, 11-point verbal numeric rating scale (0 = no pain to 10 = worst possible pain).

higher in patients from Europe at the 3-month follow-up (85.0% vs. 70.2%), the difference dissipated at later follow-up times including the last visit (Fig. 2).

Safety

Among the 1290 patients with safety data available, 48 had their devices explanted (3.7%) (Table 2). Of these, 22 were removed sequela to infection (1.7%), 15 due to loss of efficacy (1.2%), and 11 for other reasons (0.8%).

Ease of use

While a high percentage of patients responded well to standard 10 kHz target optimization using a simple bipole, additional 10 kHz therapy optimization tools were utilized in 56.7% of all patients (N = 1198) (Fig. 3). These programming options were applied in a standardized fashion and customized to each patient’s needs. In total, 38.3% of all patients (N = 1198) had multi-area pain sequencing (MAPS) or bipole interlacing programmed. The former option combined different programs while the latter merged multiple bipole programs into one program. Pulse dosing was programmed in 18.4% of the population (N = 1198) and delivered stimulation in on-off cycles.

Interestingly, additional 10 kHz therapy optimization tools were utilised in 72.7% of patients from Europe (N = 391) and in 48.9% of patients from the USA (N = 807) (Fig. 3). More specifically, MAPS or bipole interlacing was programmed in 54.9% and 30.2% of Europe and USA patients, respectively, while pulse dosing was programmed in 17.8% and 18.7%, respectively.

Quality of life

Functional improvement at the last visit was noted by 72.3% of all patients (N = 1088), 78.8% of Europe patients (N = 311), and 69.8% of USA patients (N = 777) (Fig. 3). Improved sleep was reported by 68.0% of all patients (N = 1020), 68.5% of Europe patients (N = 286), and 67.8% of USA patients (N = 734).

Additional responses to questions at the last visit which evaluated overall change in quality of life, satisfaction with therapy, device recharge experience, frequency of therapy adjustments, and device usage while sleeping and driving are detailed in Table 3. Data were available for between 533 and 544 patients for all questions except that which focused on patients with previous LF-SCS experience which had 60 responses.

When questioned about overall change in quality of life, 90.3% of patients reported improvement. High levels of satisfaction with therapy were also reported by most patients: 82.4% were likely or very likely to undergo the procedure again for the same result, 89.5% were likely or very likely to recommend the therapy, and 95.0% of patients who had previous LF-SCS experience rated their HF-SCS at 10 kHz as better. Device recharging was found to be convenient in 86.4% of patients with the majority charging their device daily or every other day (94.1%) for about an hour or less (88.7%). Patients rarely adjusted their therapy more often than 2–3 times per week (2.2%). Nearly all patients slept and drove with their devices switched on (98.7% and 98.2%, respectively). The responses to this set of questions were generally in line with the commercial data from all implanted patients in USA (N = 8282; Table 3).

Medication change

Overall change in medication versus baseline was also analyzed at the last visit. A decrease in medication intake was reported by 32.1% of all patients (N = 1070), 40.0% of Europe patients (N = 310), and 28.9% of USA patients (N = 760) (Fig. 3).
Patients with previous LF-SCS

Outcomes were analyzed as they related to the subgroup of patients with previously unsuccessful LF-SCS. The results of HF-SCS in this patient subgroup were comparable to the results for the entire cohort. Pain distribution data \( (N = 382) \) indicated that 47.6% had back and leg pain, 26.7% predominant back pain, 10.7% predominant leg pain, and 14.9% other pain distributions. Median pain intensity score at baseline was 8.0 (Q1–Q3, 7.0–9.0) \( (N = 337) \). The mean time between implantation and the last visit was 10.7 months \( (\text{mean} \pm \text{SD}) \). Successful trials were reported in 88.4% of this group \( (298/337) \). Pain intensity scores in trial responders reduced significantly \( (P < 0.0001, \text{Mann–Whitney} \ U \text{test}) \). Median scores reduced from 8.0 (Q1–Q3, 7.0–9.0) to 3.0 (Q1–Q3, 1.8–4.0) points, a reduction of 62.5%. At 3, 6, and 12 months post-implantation, 75.6% \( (N = 193) \), 72.1% \( (N = 147) \), and 78.9% \( (N = 90) \) of patients responded to therapy, respectively \( (\text{Fig. 2}) \). Of the 266 patients with percentage pain relief data available at the last visit, 74.1% responded to therapy. At the last visit, 32.5% of patients \( (N = 40) \) reported decreased medication intake versus baseline, 82.5% \( (N = 40) \) improved function, and 70.0% \( (N = 30) \) improved sleep. Responses to questions at the last visit which evaluated overall change in quality of life, satisfaction with therapy, device recharge experience, frequency of therapy adjustments, and device usage while sleeping and driving were very similar to the whole cohort of patients \( (\text{Table 3}) \).

Discussion

This publication constitutes the most extensive study to date evaluating the real-world efficacy of HF-SCS 10 kHz therapy for chronic back and/or limb pain. Data were retrospectively sourced from eight participating centers across three countries over a 4-year period. A total of 1660 patients were included in the review. The majority of the cohort had both chronic back and leg pain or axial back pain (71%), which are historically difficult-to-treat pain syndromes. Our review found that >70% of our HF-SCS treated patients experienced at least 50% pain relief throughout 12 months of post-implantation follow-up. This outcome was corroborated by the last visit analysis. Concomitant improvements in quality of life, function, sleep, and medication reduction as well as high levels of satisfaction with the therapy were also reported.

Therapeutic and device durability was found to be robust as evidenced by an extremely low explantation rate. The overall rate of system explant was 3.7%, far less than historical norms for traditional spinal cord stimulation (LF-SCS).\(^{24}\) Explants due to infection were 1.7% of implants. This value is slightly lower than the published historical rates of LF-SCS infection of 3-5%.\(^{25}\) Explants due to loss of efficacy occurred in 1.2% of the implanted population. Behind battery depletion in non-rechargeable IPGs, explants due to loss of efficacy are the predominant driver for historical LF-SCS explantations; thus, the low rates of explant for this reason are highly encouraging. There were no explants due to battery depletion.

Table 2. Details of device explants in the population.

| Reason for explant | n (%; 95% confidence range) |
|-------------------|-----------------------------|
| Infection         | 22 (1.7%; 1.0%–2.4%)        |
| Loss of efficacy  | 15 (1.2%; 0.6%–1.8%)        |
| Other reasons     | 11 (0.8%; 0.3%–1.3%)        |
| Total             | 48 (3.7%; 2.7%–4.7%)        |

Figure 2. Responder rate (±95% confidence interval) at each study time point.
Figure 3. Evaluation of therapy optimization tools (10 kHz preferred program) and overall change in medication, function, and sleep, at the last visit. Therapy optimization tools: Multi-area pain sequencing (MAPS) combines different programs; bipole interlacing merges multiple bipole programs into one program; pulse dosing delivers stimulation in on-off cycles. Values given as % with 95% confidence interval.
Table 3. Responses to questions which evaluated overall change in quality of life, satisfaction with therapy, device recharge experience, frequency of therapy adjustments, and device usage while sleeping and driving. Based on data available at the last visit from USA patients. Data is presented as % (95% confidence lower limit-upper limit).

| Question                                                                 | Patients in this review\(^1\) | Subgroup of patients with previous LF-SCS experience in this review\(^2\) | Comparative cohort: patients from the entire USA\(^3\) |
|-------------------------------------------------------------------------|-------------------------------|--------------------------------------------------------------------------|--------------------------------------------------|
| Overall change in quality of life                                       | \(N = 544\)                  | \(N = 140\)                                                              | \(N = 8283\)                                      |
| Since having your device, how would you describe the change in activity limitations, symptoms, emotions and overall quality of life? |                               |                                                                          |                                                  |
| A great deal better                                                     \(56.6\% \ (52.4\% - 60.8\%\) | \(51.4\% \ (43.1\% - 59.7\%\) | \(56.3\% \ (55.2\% - 57.4\%\) |
| Moderately better                                                       \(33.6\% \ (29.6\% - 37.6\%\) | \(36.4\% \ (28.4\% - 48.4\%\) | \(30.4\% \ (29.4\% - 31.4\%\) |
| No change                                                               \(9.7\% \ (7.2\% - 12.2\%\) | \(12.1\% \ (6.7\% - 17.5\%\) | \(13.3\% \ (12.6\% - 14.0\%\) |
| Satisfaction with therapy                                              |                               |                                                                          |                                                  |
| How likely are you to do it all again for the result you are getting now? | \(N = 544\)                  | \(N = 140\)                                                              | \(N = 8276\)                                      |
| Likely or very likely                                                  \(82.4\% \ (79.2\% - 85.6\%\) | \(81.4\% \ (75.0\% - 87.8\%\) | \(79.0\% \ (78.1\% - 79.9\%\) |
| Not sure                                                               \(11.8\% \ (9.1\% - 14.5\%\) | \(12.9\% \ (7.3\% - 18.5\%\) | \(10.9\% \ (10.2\% - 11.6\%\) |
| Unlikely or very unlikely                                              \(5.9\% \ (3.9\% - 7.9\%\) | \(5.7\% \ (1.7\% - 9.5\%\) | \(10.1\% \ (9.5\% - 10.7\%\) |
| How likely are you to recommend Nevro\(^4\) to someone who has similar pain? | \(N = 544\)                  | \(N = 140\)                                                              | \(N = 8183\)                                      |
| Likely or very likely                                                  \(89.5\% \ (86.9\% - 92.1\%\) | \(85.7\% \ (79.9\% - 91.5\%\) | \(84.7\% \ (83.9\% - 85.5\%\) |
| Not sure                                                               \(7.6\% \ (5.4\% - 9.8\%\) | \(9.3\% \ (4.5\% - 14.1\%\) | \(10.9\% \ (10.2\% - 11.6\%\) |
| Unlikely or very unlikely                                              \(3.0\% \ (1.6\% - 4.4\%\) | \(5.0\% \ (1.4\% - 8.6\%\) | \(4.5\% \ (4.1\% - 4.9\%\) |
| How would you rate the Nevro\(^4\) device in comparison to the previous SCS \(^5\) you experienced? | \(N = 60\)                  | \(N = 920\)                                                              |                                                  |
| A great deal better                                                     \(90.0\% \ (82.4\% - 97.6\%\) | \(76.8\% \ (74.1\% - 79.5\%\) |                                                  |
| Moderately better                                                       \(5.0\% \ (0\% - 10.5\%\) | \(11.0\% \ (9.0\% - 13.0\%\) |                                                  |
| No change                                                               \(5.0\% \ (0\% - 10.5\%\) | \(12.2\% \ (10.1\% - 14.3\%\) |                                                  |
| Device recharge experience                                             | \(N = 544\)                  | \(N = 140\)                                                              | \(N = 8276\)                                      |
| How satisfied are you with the convenience of charging your device?     |                               |                                                                          |                                                  |
| Satisfied or very satisfied                                            \(86.4\% \ (83.5\% - 89.3\%\) | \(83.6\% \ (77.5\% - 89.7\%\) | \(74.5\% \ (73.6\% - 75.4\%\) |
| Neutral                                                                \(7.4\% \ (5.2\% - 9.6\%\) | \(9.3\% \ (4.5\% - 14.1\%\) | \(15.8\% \ (15.0\% - 16.6\%\) |
| Dissatisfied or very dissatisfied                                       \(6.3\% \ (4.3\% - 8.3\%\) | \(7.1\% \ (2.8\% - 11.4\%\) | \(9.7\% \ (9.1\% - 10.3\%\) |
| How often do you charge your device?                                   | \(N = 544\)                  | \(N = 140\)                                                              | \(N = 8265\)                                      |
| Every day                                                              \(81.8\% \ (78.6\% - 85.0\%\) | \(77.1\% \ (70.1\% - 84.1\%\) | \(81.3\% \ (80.5\% - 82.1\%\) |
| Every other day                                                        \(12.3\% \ (9.5\% - 15.1\%\) | \(18.6\% \ (12.2\% - 25.0\%\) | \(13.4\% \ (12.7\% - 14.1\%\) |
| Less than 2–3 times per week                                           \(5.7\% \ (3.8\% - 7.6\%\) | \(3.6\% \ (0.5\% - 6.7\%\) | \(4.8\% \ (4.3\% - 5.3\%\) |

\(^1\) Question 1, \(^2\) Question 2, \(^3\) Question 3, \(^4\) Question 4, \(^5\) Question 5

(Continued)
**Table 3.** Continued.

| Question | Patients in this review¹ | Subgroup of patients with previous LF-SCS experience in this review² | Comparative cohort: patients from the entire USA³ |
|----------|-------------------------|------------------------------------------------------------------|-----------------------------------------------|
| **Frequency of therapy adjustments** | | | |
| How long does it take you to charge your device? | | | |
| <30 min | 23.5% (19.9%–27.1%) | 20.9% (14.0%–27.8%) | 21.8% (20.9%–22.7%) |
| 30–60 min | 65.3% (61.3%–69.3%) | 61.9% (53.7%–70.1%) | 70.9% (69.9%–71.9%) |
| > 60 min | 11.3% (8.6%–14.0%) | 17.2% (10.8%–23.6%) | 7.3% (6.7%–7.9%) |
| **Device usage while sleeping and driving** | | | |
| How often do you use your remote control to adjust your therapy settings? | N = 544 | N = 140 | N = 8272 |
| Never | 50.6% (46.4%–54.8%) | 47.1% (38.8%–55.4%) | 46.8% (45.7%–47.9%) |
| Once per week or less often | 34.6% (30.6%–38.6%) | 37.9% (29.9%–45.9%) | 38.8% (37.8%–39.8%) |
| 2–3 times per week | 12.7% (9.9%–15.5%) | 13.6% (7.9%–19.3%) | 11.3% (10.6%–12.0%) |
| Daily | 2.2% (1.0%–3.4%) | 1.4% (0–3.3%) | 3.1% (2.7%–3.5%) |
| Do you sleep with your device turned on? | N = 544 | N = 140 | N = 8274 |
| Yes | 98.7% (97.7%–99.7%) | 98.6% (96.7%–100.5%) | 98.8% (98.6%–99.0%) |
| No | 1.3% (0.3%–2.3%) | 1.4% (0–3.3%) | 1.2% (1.0%–1.4%) |
| Do you drive with your device turned on? | N = 543 | N = 140 | N = 8266 |
| Yes | 98.2% (97.1%–99.3%) | 97.9% (95.5%–100.3%) | 97.8% (97.5%–98.1%) |
| No | 1.8% (0.7%–2.9%) | 2.1% (0–4.5%) | 2.2% (1.9%–2.5%) |

¹Mean follow-up period = 8.9 months (SD ±6.7, range 0.1–33.2).
²Mean follow-up period = 10.7 months (SD ±7.7, range 0.1–33.2).
³Total number of responses from implanted patients in USA = 8282. Mean follow-up period = 8.1 months (SD ± 5.2, range 0.3–26.4).
⁴Nevro refers to HF-SCS at 10 kHz therapy.
⁵SCS refers to LF-SCS therapy.
Device recharging was generally found to be convenient with most patients recharging daily, or every other day for an hour or less. Paresthesia-independent stimulation is likely to account for the vast majority of patients (98% or more) who rarely adjusted their therapy settings once optimal pain relief was achieved, and reported sleeping and driving with their devices switched on. Our analysis also showed that therapy can be tailored to individual patients, with patients finding their most successful program across a range of different applications of 10 kHz therapy. Further subgroup analysis of patients with previously unsuccessful LF-SCS revealed that their outcomes were very similar to the whole cohort, indicating that 10 kHz HF-SCS therapy may be a useful treatment option for this group.

Our responder rate outcomes are consistent with results from a multicenter, prospective, randomized, controlled trial (SENZA-RCT) comparing the therapy with LF-SCS. Recruited subjects had chronic, intractable, back and leg pain with average pain intensity in both locations of at least 5.0 cm on the visual analog scale (VAS). The SENZA-RCT longitudinal responder rates for axial back pain in HF-SCS 10 kHz subjects were 84%, 76%, and 79% at 3, 6, and 12 months, respectively. The corresponding rates for overall pain relief in our cohort were comparable (Fig. 4). Furthermore, 32% of our patients reported decreased medication intake at their last visit. This proportion is in line with the 36% of subjects receiving HF-SCS 10 kHz in the SENZA-RCT who reduced or stopped opioid pain medication at 12 months.

Overall, the patient populations in both studies were broadly similar in their primary indication of chronic back and leg pain. The Level I evidence provided by the SENZA-RCT has been strengthened by the contribution of our real-world data from a large cohort of patients across multiple international centers and is likely to reflect everyday clinical practice. The consistent reduction in medication consumption found in both studies is potentially beneficial to patients as well as health care providers since it may reduce prescription costs and visits to pharmacy.

Limitations of this review are related to the real-world setting and include its retrospective nature, lack of control group and use of non-standardized measures for outcomes such as sleep. Data were not entered systematically across all centers and some patients may have been included in early follow-ups, but not later ones, and vice-versa. Both factors resulted in an inhomogeneous data set with a declining patient number throughout follow-up. In addition, longitudinal data were available only for percentage pain relief. All other post-implantation variables were collected during a single last visit assessment. The real-world setting also prevented the collection of specific pain etiologies and implantation details as well as standardized measures of medication intake, quality of life, function, and sleep. For example, the simplified measures we used did not evaluate pain medication intake by class, quality of life parameters relating to health and physical or social activities, or assessment of sleep latency and quality. As such these results should be interpreted with caution.

Figure 4. Comparison of responder rates (±95% confidence interval) between this real-world study and the SENZA-RCT.
Other limitations relate to our data analysis. Evaluating data as-observed may overestimate response.\(^\text{26}\) In addition, given the non-normal distribution of the data, non-parametric statistics with mixed model approach using study as a fixed categorical factor and period as a repeated categorical fixed factor may have been a better choice for longitudinal analysis of pain relief. However, because the data was collected in a real-world setting and completely anonymized, pain relief data in a specified line could not be attributed to a single subject. Therefore, it was not possible to apply mixed model approach and only descriptive statistics could be used to analyze the data. Data distribution should be borne in mind while interpreting these results. Furthermore, evaluation of outcomes in patients with previously unsuccessful LF-SCS requires a larger population of patients to allow adequate statistical analysis.

Finally, there were methodological differences related to study design and patient characteristics regarding the comparison of our responder rates to those reported in the SENZA-RCT. For example, our study evaluated overall pain relief rather than separate back and leg pain relief (derived from VAS) as measured in the SENZA-RCT. Our measure was a pragmatic choice to enable quick assessment of therapy effectiveness during routine follow-up. Also, in our experience, percentage pain relief is a more straightforward concept to convey and understand in the real-world setting compared with VNRS or VAS. In cases where back and leg pain were reported equal, back pain may have been slightly predominant, but not identified by our verbal questions.

**Conclusions**

The present study was designed to evaluate the real-world effectiveness of HF-SCS at 10 kHz in a large group of patients with chronic trunk and/or limb pain. Our retrospective analysis revealed that the therapy provided sustained and effective pain relief in >70% of the patients at all follow-up time points. This result was consistent with a previously published randomized, controlled, trial. The majority of our patients also reported improved quality of life, function, and sleep, as well as satisfaction with therapy. Our review provides complementary evidence to support the treatment of chronic back and leg pain with HF-SCS at 10 kHz.

**Author Contributions**

All the authors have reviewed and approved the final version of this manuscript. D. Edgar prepared the manuscript with unrestricted access to the data. Authors thank the contribution of M. Kowalska, M. Maneshi of Nevro Corp. for their assistance in data analysis and J.-L. Marchal, InforStat Consultants, Belgium for help with statistical analysis.

**Conflict of Interest**

T. Stauss, G. Surges, D. Sayed, F. El Majdoub, W. S. Rosenberg, L. Kapural, R. Bundschu, A. Lalkhen, M. Maarouf and N. Patel are consultants to Nevro Corp., Redwood City, CA, USA. B. Gliner, J. Subbaroyan, and A. Rotte are employees of Nevro Corp., Redwood City, CA, USA. Funding was provided to Dr. Deborah Edgar in her capacity as a medical writer by Nevro Corp., Redwood City, CA, USA, for the preparation of this manuscript.

**References**

1. International Association for the Study of Pain: Unrelieved pain is a major global healthcare problem. URL: https://s3.amazonaws.com/rcms-iasp/files/production/public/Content/ContentFolders/GlobalYearAgainstPain2/20042005RighttoPainRelief/factsheet.pdf. Access date: 30th April 2018.
2. Goldberg DS, McGee SJ. Pain as a global public health priority. BMC Public Health 2011;6:770.
3. Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin Proc 2015;90:139–147.
4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211–1259.
5. Thomson S. Failed back surgery syndrome – definition, epidemiology and demographics. Br J Pain 2013;7:56–59.
6. Thomson S, Jacques L. Demographic characteristics of patients with severe neuropathic pain secondary to failed back surgery syndrome. Pain Pract 2009;9:206–215.
7. North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery 2005;56:98–106; discussion -7.
8. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain 2007;132:179–188.
9. Kapural L, Peterson E, Provenzano DA, Stasts P. Clinical evidence for spinal cord stimulation for failed back surgery syndrome (FBSS): systematic review. Spine 2017;15(42 Suppl 14):S61–S66.
10. Kupers RC, Van den Oever R, Van Houdenhove B, et al. Spinal cord stimulation in Belgium: a nation-wide survey.
on the incidence, indications and therapeutic efficacy by
the health insurer. Pain 1994;56:211–216.
11. Ohnmeiss DD, Rashbaum RF, Bogdanffy GM. Prospective
outcome evaluation of spinal cord stimulation in patients
with intractable leg pain. Spine 1996;21:1344–1350;
discussion 51.
12. Alo KM, Redko V, Charnov J. Four year follow-up of dual
electrode spinal cord stimulation for chronic pain.
Neuromodulation 2002;5:79–88.
13. Cameron T. Safety and efficacy of spinal cord
stimulation for the treatment of chronic pain: a 20-year
literature review. J Neurosurg 2004;100(3 Suppl
Spine):254–267.
14. Sears NC, Machado AG, Nagel SJ, et al. Long-term
outcomes of spinal cord stimulation with paddle leads in
the treatment of complex regional pain syndrome and
failed back surgery syndrome. Neuromodulation
2011;14:312–318; discussion 8.
15. Kumar K, Hunter G, Demeria D. Spinal cord stimulation
in treatment of chronic benign pain: challenges in
treatment planning and present status, a 22-year
experience. Neurosurgery 2006;58:481–496; discussion -96.
16. Provenzano DA, Amirdelfan K, Kapural L, Sitzman BT.
Evidence gaps in the use of spinal cord stimulation for
treating chronic spine conditions. Spine 2017;15(42 Suppl
14):S80–S92.
17. Kuechmann C, Valine T, Wolfe DL. 853 could automatic
position adaptive stimulation be useful in spinal cord
stimulation? Eur J Pain 2009;13:S243.
18. Levy RM. Anatomic considerations for spinal cord
stimulation. Neuromodulation 2014;17(Suppl 1):2–11.
19. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz
high-frequency and traditional low-frequency spinal cord
stimulation for the treatment of chronic back and leg pain: 24-month results from a multicenter, randomized.
Controlled Pivotal Trial. Neurosurgery 2016;79:667–677.
20. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-
frequency therapy (HF10 therapy) is superior to traditional
low-frequency spinal cord stimulation for the treatment of
chronic back and leg pain: the SENZA-RCT randomized
controlled trial. Anesthesiology 2015;123:851–860.
21. Spieth PM, Kubasch AS, Penzlin AI, et al. Randomized
controlled trials - a matter of design. Neuropsychiatr Dis
Treat 2016;12:1341–1349.
22. Frieden TR. Evidence for health decision making - beyond
randomized, controlled trials. N Engl J Med 2017;377:465–475.
23. Price D, Bateman ED, Chisholm A, et al. Complementing
the randomized controlled trial evidence base. Evolution
not revolution. Ann Am Thorac Soc 2014;11(Suppl 2):
S92–S98.
24. Hayek SM, Veizi E, Hanes M. Treatment-limiting
complications of percutaneous spinal cord stimulator
implants: a review of 8 years of experience from an
academic center database. Neuromodulation 2015;18:603–
608; discussion 8–9.
25. Provenzano DA, Deer T, Luginbuhl Phelps A, et al. An
international survey to understand infection control
practices for spinal cord stimulation. Neuromodulation
2016;19:71–84.
26. Amin M, No DJ, Darji K, Wu JJ. Interpreting clinical trial
data. In: P. S. Yamauchi, ed. Biologic and Systemic Agents
in Dermatology. pp. 27–36, 1st edn. Cham: Springer, 2018